A wholly-owned subsidiary of Bupa Care Homes, Stockport-based SurgiChem is a provider of medication adherence packaging to the UK care home and domiciliary care markets.
The company supplies monitored dosage systems to a network of over 3,200 independent pharmacies and larger UK pharmacy chains.
Surgichem will be integrated with Omnicell’s existing UK business, MTS Medication Technologies, in the coming months.
Randall Lipps, chairman, president and chief executive of Omnicell, said healthcare professionals and caregivers are always seeking to improve patient outcomes, reduce medication errors and lower costs through effectively managing compliance to prescribed medication regimes.
“Omnicell is committed to improving medication adherence in the UK. We expect that combining the leading multi- and single-dose packaging technologies of MTS Medication Technologies with the very complementary Surgichem offering will help to solve the issue by speeding the development of new products and services for the UK adherence market.”
Some figures suggest around half of patients in developed countries do not take their medications as prescribed, and up to two-thirds of all medication-related hospitalisations is the result of non-adherence.
According to an Aston University study, medication non-adherence costs up to 500m annually in the UK.
